Literature DB >> 12568398

Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells.

Chaoxiang Shui1, Thomas C Spelsberg, B Lawrence Riggs, Sundeep Khosla.   

Abstract

Runx2/Cbfa1 has been identified as a "master gene" controlling osteoblast differentiation. However, its role in inducing the osteoblast phenotype has been characterized primarily in rodent systems. Thus, we examined Runx2/Cbfa1 messenger RNA, protein, and activity levels during osteoblastic differentiation of human bone marrow stromal (BMSC) cells. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis demonstrated that the expression of alkaline phosphatase and osteocalcin mRNAs increased in a time-dependent manner with the development of the osteoblast phenotype by these cells (hMS2-15). Type II Runx2/Cbfa1 messenger RNA was found to be constitutively expressed in hMS2-15 cells and not altered during differentiation; there was no detectable expression of the type I Runx2/Cbfa1 transcript. Interestingly, despite the absence of any change in Runx2/Cbfa1 messenger RNA levels during osteoblastic differentiation of these cells, the activity of Runx2/Cbfa1, as assessed by binding to the osteoblast-specific cis-acting element 2 (OSE2), increased markedly at all time-points examined, with the highest activity level seen at day 7. Similar results were observed in primary cultures of less differentiated human marrow-derived mesenchymal stem cells. Immunoprecipitation and Western blot analysis revealed that whereas there was no increase in Runx2/Cbfa1 protein levels with differentiation in hMS2-15 cells, there was an increase in Runx2/Cbfa1 phosphorylation. Thus, in contrast to rodent systems where osteoblast differentiation is associated with increased synthesis of Runx2/Cbfa1, we find that in human BMSC, osteoblastic differentiation is associated primarily with increases in Runx2/Cbfa1 activity, without a change in messenger RNA or protein levels. Our findings also show that the increase in Runx2/Cbfa1 activity occurs through a posttranslational mechanism involving phosphorylation of key residues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12568398     DOI: 10.1359/jbmr.2003.18.2.213

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  67 in total

1.  Runx2 overexpression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects.

Authors:  Abigail M Wojtowicz; Kellie L Templeman; Dietmar W Hutmacher; Robert E Guldberg; Andrés J García
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  [Effects of mechanical strain on human osteoblastic precursor cells in type I collagen matrices].

Authors:  A Ignatius; H Blessing; A Liedert; D Kaspar; L Kreja; B Friemert; L Claes
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

4.  Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.

Authors:  Didier Merciris; Caroline Marty; Corinne Collet; Marie-Christine de Vernejoul; Valerie Geoffroy
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

5.  Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation.

Authors:  Nagarajan Selvamurugan; Emi Shimizu; Minnkyong Lee; Tong Liu; Hong Li; Nicola C Partridge
Journal:  FEBS Lett       Date:  2009-03-03       Impact factor: 4.124

6.  Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels.

Authors:  Wen-Tzu Lai; Veena Krishnappa; Donald G Phinney
Journal:  Stem Cells       Date:  2011-07       Impact factor: 6.277

7.  IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway.

Authors:  Cong-Xiang Jian; Quan-Shui Fan; Yong-He Hu; Yong He; Ming-Zhe Li; Wei-Yin Zheng; Yu Ren; Chen-Jun Li
Journal:  Organogenesis       Date:  2016-08-31       Impact factor: 2.500

8.  Hyaluronic acid hydrogels incorporating platelet lysate enhance human pulp cell proliferation and differentiation.

Authors:  Leopoldina D F Almeida; Pedro S Babo; Cristiana R Silva; Márcia T Rodrigues; Josimeri Hebling; Rui L Reis; Manuela E Gomes
Journal:  J Mater Sci Mater Med       Date:  2018-06-14       Impact factor: 3.896

9.  Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.

Authors:  Liping Wang; Xiaoyou Shi; Rong Zhao; Bernard P Halloran; David J Clark; Christopher R Jacobs; Wade S Kingery
Journal:  Bone       Date:  2009-12-02       Impact factor: 4.398

10.  Implant surface treatments affect gene expression of Runx2, osteogenic key marker.

Authors:  Young Na; Seong-Joo Heo; Seong-Kyun Kim; Jai-Young Koak
Journal:  J Adv Prosthodont       Date:  2009-07-31       Impact factor: 1.904

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.